Cargando…

COVID‐19: Current knowledge in clinical features, immunological responses, and vaccine development

The COVID‐19 pandemic has unfolded to be the most challenging global health crisis in a century. In 11 months since its first emergence, according to WHO, the causative infectious agent SARS‐CoV‐2 has infected more than 100 million people and claimed more than 2.15 million lives worldwide. Moreover,...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Ramandeep, Kang, Alisha, Luo, Xiangqian, Jeyanathan, Mangalakumari, Gillgrass, Amy, Afkhami, Sam, Xing, Zhou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898934/
https://www.ncbi.nlm.nih.gov/pubmed/33577115
http://dx.doi.org/10.1096/fj.202002662R
_version_ 1783653969129635840
author Singh, Ramandeep
Kang, Alisha
Luo, Xiangqian
Jeyanathan, Mangalakumari
Gillgrass, Amy
Afkhami, Sam
Xing, Zhou
author_facet Singh, Ramandeep
Kang, Alisha
Luo, Xiangqian
Jeyanathan, Mangalakumari
Gillgrass, Amy
Afkhami, Sam
Xing, Zhou
author_sort Singh, Ramandeep
collection PubMed
description The COVID‐19 pandemic has unfolded to be the most challenging global health crisis in a century. In 11 months since its first emergence, according to WHO, the causative infectious agent SARS‐CoV‐2 has infected more than 100 million people and claimed more than 2.15 million lives worldwide. Moreover, the world has raced to understand the virus and natural immunity and to develop vaccines. Thus, within a short 11 months a number of highly promising COVID‐19 vaccines were developed at an unprecedented speed and are now being deployed via emergency use authorization for immunization. Although a considerable number of review contributions are being published, all of them attempt to capture only a specific aspect of COVID‐19 or its therapeutic approaches based on ever‐expanding information. Here, we provide a comprehensive overview to conceptually thread together the latest information on global epidemiology and mitigation strategies, clinical features, viral pathogenesis and immune responses, and the current state of vaccine development.
format Online
Article
Text
id pubmed-7898934
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-78989342021-03-03 COVID‐19: Current knowledge in clinical features, immunological responses, and vaccine development Singh, Ramandeep Kang, Alisha Luo, Xiangqian Jeyanathan, Mangalakumari Gillgrass, Amy Afkhami, Sam Xing, Zhou FASEB J Reviews The COVID‐19 pandemic has unfolded to be the most challenging global health crisis in a century. In 11 months since its first emergence, according to WHO, the causative infectious agent SARS‐CoV‐2 has infected more than 100 million people and claimed more than 2.15 million lives worldwide. Moreover, the world has raced to understand the virus and natural immunity and to develop vaccines. Thus, within a short 11 months a number of highly promising COVID‐19 vaccines were developed at an unprecedented speed and are now being deployed via emergency use authorization for immunization. Although a considerable number of review contributions are being published, all of them attempt to capture only a specific aspect of COVID‐19 or its therapeutic approaches based on ever‐expanding information. Here, we provide a comprehensive overview to conceptually thread together the latest information on global epidemiology and mitigation strategies, clinical features, viral pathogenesis and immune responses, and the current state of vaccine development. John Wiley and Sons Inc. 2021-02-12 2021-03 /pmc/articles/PMC7898934/ /pubmed/33577115 http://dx.doi.org/10.1096/fj.202002662R Text en © 2021 The Authors. The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Reviews
Singh, Ramandeep
Kang, Alisha
Luo, Xiangqian
Jeyanathan, Mangalakumari
Gillgrass, Amy
Afkhami, Sam
Xing, Zhou
COVID‐19: Current knowledge in clinical features, immunological responses, and vaccine development
title COVID‐19: Current knowledge in clinical features, immunological responses, and vaccine development
title_full COVID‐19: Current knowledge in clinical features, immunological responses, and vaccine development
title_fullStr COVID‐19: Current knowledge in clinical features, immunological responses, and vaccine development
title_full_unstemmed COVID‐19: Current knowledge in clinical features, immunological responses, and vaccine development
title_short COVID‐19: Current knowledge in clinical features, immunological responses, and vaccine development
title_sort covid‐19: current knowledge in clinical features, immunological responses, and vaccine development
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898934/
https://www.ncbi.nlm.nih.gov/pubmed/33577115
http://dx.doi.org/10.1096/fj.202002662R
work_keys_str_mv AT singhramandeep covid19currentknowledgeinclinicalfeaturesimmunologicalresponsesandvaccinedevelopment
AT kangalisha covid19currentknowledgeinclinicalfeaturesimmunologicalresponsesandvaccinedevelopment
AT luoxiangqian covid19currentknowledgeinclinicalfeaturesimmunologicalresponsesandvaccinedevelopment
AT jeyanathanmangalakumari covid19currentknowledgeinclinicalfeaturesimmunologicalresponsesandvaccinedevelopment
AT gillgrassamy covid19currentknowledgeinclinicalfeaturesimmunologicalresponsesandvaccinedevelopment
AT afkhamisam covid19currentknowledgeinclinicalfeaturesimmunologicalresponsesandvaccinedevelopment
AT xingzhou covid19currentknowledgeinclinicalfeaturesimmunologicalresponsesandvaccinedevelopment